Evaluation of product bioequivalence when subject blood volume necessitates limited sampling strategies
In a traditional blood level bioequivalence (BE) study, every subject provides drug concentrations at each blood sampling time. However, this approach is not suitable for animals whose blood volume limits or prohibits multiple sample collections. In our previous research, we presented an approach th...
Saved in:
| Published in | Journal of veterinary pharmacology and therapeutics Vol. 46; no. 5; pp. 276 - 299 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
England
01.09.2023
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0140-7783 1365-2885 1365-2885 |
| DOI | 10.1111/jvp.13125 |
Cover
| Summary: | In a traditional blood level bioequivalence (BE) study, every subject provides drug concentrations at each blood sampling time. However, this approach is not suitable for animals whose blood volume limits or prohibits multiple sample collections. In our previous research, we presented an approach that can be applied to studies using a destructive sampling design where each animal provides only 1 blood sample that is then incorporated into a composite profile. Another situation we sometimes face is that of when the animals can contribute more than one sample but are still limited in the number of blood draws (e.g., 3) such that a complete profile per animal is not feasible. Unlike the destructive sampling situation, we cannot combine all blood samples into a single “composite” profile and ignore the correlation of values obtained from the same subject. To avoid the complexities associated with needing to include a covariance component among experimental units into the statistical model, we propose an approach whereby study subjects are randomly assigned to housing unit (e.g., cage or pen) and then randomly assigned to a sampling schedule within each housing unit. In doing so, housing unit rather than the individual subject serves as the experimental unit. This article provides an assessment of this alternative approach to assess product BE when only a limited number of samples can be obtained per study subject. |
|---|---|
| Bibliography: | The information in these materials is not a formal dissemination of information by FDA and does not constitute an advisory opinion, does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| ISSN: | 0140-7783 1365-2885 1365-2885 |
| DOI: | 10.1111/jvp.13125 |